C

Chemours

Produces titanium dioxide, refrigerants, and Teflon

Electrical & Instrumentation Process Engineer

Full-Time
$110.5k - $172.7k+ 11% Annual Bonus Target + 401(k) Match
Senior
Bachelor's
El Dorado, AR, USA+1 moreMore locations: La Porte, TX, USA
In PersonTravel up to 25% may be required.
Electrical EngineeringControls & Automation Engineering
No H1B Sponsorship

About the job

Requirements
  • A Bachelor of Science in Electrical Engineering is required.
  • At least 5 years of electrical and/or reliability engineering experience in a manufacturing or industrial environment is required.
  • Demonstrated experience working with field maintenance personnel in troubleshooting and hands-on support is required.
  • Proficient computer skills, including use of engineering software and data tools, are required.
  • A proven background in the design, specification, installation, and maintenance of electrical and instrumentation systems is required.
  • A thorough understanding of the National Electrical Code (NEC), including requirements for hazardous (classified) locations, is required.
  • The ability to perform and document Root Cause Failure Analyses (RCFA) is required.
  • Experience in chemical manufacturing or other Process Safety Management (PSM)-regulated industries is required.
  • Strong oral and written communication skills and the ability to communicate technical information clearly are required.
Responsibilities
  • Provide technical expertise for the reliability, maintenance, and performance of plant electrical and instrumentation systems.
  • Oversee and ensure safe operation of electrical distribution systems, including compliance with NEC, NFPA 70E, and facility electrical safety procedures.
  • Support PSM-covered processes through participation in Management of Change (MOC), Process Hazard Analyses (PHA), equipment evaluations, and compliance reviews.
  • Lead and facilitate Root Cause Failure Analyses (RCFA) and drive corrective actions to prevent recurrence.
  • Partner with maintenance and operations teams to troubleshoot equipment issues and implement long-term reliability improvements.
  • Develop, review, and approve specifications for electrical components, instrumentation, and control systems.
  • Provide guidance for installation, testing, and commissioning of electrical and instrumentation systems.
  • Analyze maintenance and performance data to identify trends, failure patterns, and improvement opportunities.
  • Contribute to equipment reliability programs, including preventive, predictive, and condition-based maintenance strategies.
  • Support capital projects through design input, technical review, and reliability evaluations.
  • Promote a strong safety culture and ensure compliance with relevant codes, standards, and internal policies.
  • Champion reliability culture through standard work practices and resource recommendations.
  • Become a subject matter expert in area-specific equipment and support skill development and training.
  • Provide technical assistance to develop and implement Mechanical Integrity/Quality Assurance, reliability, and PPM programs for electrical equipment, instrumentation, valves, and power distribution.
Desired Qualifications
  • At least 10 years of experience in the manufacturing or industrial sector is preferred.
  • Experience using a Computerized Maintenance Management System (CMMS), such as SAP, is preferred.
  • Experience applying Lean methodologies to maintenance processes and supporting the implementation of business systems is preferred.
  • Certified Maintenance and Reliability Professional (CMRP) certification is preferred.
  • Advanced knowledge of data analysis, failure analysis techniques, and reliability engineering best practices is preferred.
  • A strong understanding of reliability methodologies, including Failure Modes and Effects Analysis (FMEA), Root Cause Analysis (RCA), Mean Time Between Failures (MTBF), and predictive maintenance frameworks, is preferred.
  • Familiarity with advanced reliability strategies, including Total Productive Maintenance (TPM), Overall Equipment Effectiveness (OEE), equipment uptime optimization, and life cycle cost analysis/Total Cost of Ownership (TCO), is preferred.
  • Proficiency in condition-based maintenance technologies, such as infrared thermography, ultrasonics, and performance testing and monitoring tools, is preferred.

About the company

C

Chemours

View
Website

Chemours is a chemical company formed in 2015 as a spin-off from DuPont. It focuses on producing titanium dioxide pigments, refrigerants, and the Teflon brand, along with other specialty chemicals. Its products work by delivering white pigment for paints, coatings, and plastics (titanium dioxide), providing refrigerant chemicals used in heating and cooling systems, and offering Teflon-brand materials known for their nonstick and low-frriction properties. Chemours differentiates itself from competitors through its status as an independent, focused chemical company with a clear emphasis on sustainable solutions and specialized product lines, enabled by an IPO that gave it financial independence and agility. Its goal is to lead in its core chemical markets by delivering value through chemistry—developing reliable, durable products and sustainable innovations for customers and industries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, North Carolina

Founded

2014

Get referred to Chemours

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 free cash flow reached $114 million, up 128% year over year.
  • Data-center cooling demand supports Opteon ZE and 515B sales in strategic countries.
  • August 2026 guidance held at $775 million to $825 million adjusted EBITDA despite misses.

What critics are saying

  • June 24, 2026 federal settlement costs over $450 million, crushing cash flexibility.
  • North Carolina PFAS litigation remains active, with September 2026 settlement disputes still unresolved.
  • EPA approval for Opteon 2P50 faces 17-group opposition, blocking a new growth engine.

What makes Chemours unique

  • Chemours owns Opteon and Teflon, anchoring fluorochemicals and data-center cooling.
  • Chemours' August 10, 2026 refrigerant launch targets AI-driven chillers and commercial HVAC.
  • Chemours still operates essential titanium dioxide and thermal specialty materials businesses.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Employee Stock Purchase Program
  • Tuition Reimbursement
  • Commuter Benefits
  • Learning and Development Opportunities
  • Strong Inclusion and Diversity Initiatives
  • Company-paid Volunteer Day

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

5%
CSR Company
Oct 16th, 2026
Chemours' actions toward Responsible Manufacturing.

Chemours' actions toward Responsible Manufacturing. Chemours' commitment to sustainability is rooted in its Responsible Manufacturing approach, which integrates advanced emissions reduction technologies, rigorous byproduct process analytics, and continuous improvement. This holistic framework ensures the safety, reliability, and environmental stewardship of operations and products. Chemours has set one of the most, if not the most, aggressive fluorinated organic compound (FOC) reduction targets in the world and are continuing to develop innovative technologies and processes to achieve it. Chemours has invested in the proactive development and advancement of novel analytical techniques and methodologies that enable the detection and measurement of fluorinated compounds at low levels previously not possible. Its investments in measurement and testing push the boundaries of detection beyond what regulators are requiring today. Csr Company share these advanced techniques and methodologies with regulators to enable reliable and reproducible measurements needed for meaningful emissions reduction and help advance industry wide progress. For example, the U.S. Environmental Protection Agency's (EPA) Other Test Method (OTM)-45, built to measure per- and polyfluoroalkyl substances (PFAS) in air emissions, is largely based on a sampling train designed and optimized by Chemours and also informs more updated sampling methods like OTM-50. Additionally, Chemours continues to invest in developing and improving abatement technologies. Csr Company actively engage with equipment providers to test and improve emerging technologies for air and water abatement. For example, while traditional Regenerative Thermal Oxidation (RTO) is effective for destroying dilute volatile organic compounds in high volumes of air, it faces reliability and destruction efficiency challenges when used specifically for fluorinated organic chemicals. As a result, Chemours is developing new technology in support of a reliable RTO system to more efficiently capture and destroy fluorinated compounds from dilute process streams at a high volume. Continued Progress and Investment in FOC Reduction Chemours continues to invest in technologies and implement projects to reduce FOC emissions at multiple facilities. In 2025, Csr Company completed projects to recover FM-200(TM) product emissions at its El Dorado facility in Arkansas, improve water abatement at its Washington Works and Dordrecht Works facilities, capture refrigerant emissions from loading and blending operations, and progressed improvements at several of its other manufacturing sites. This work resulted in the elimination of an additional 60 metric tons of FOC process emissions across its sites in 2025. Since 2018, Chemours has reduced its FOC process emissions by 80% or 1,313 metric tons. Chemours continues to make progress against its FOC reduction targets with more than 15 active projects underway globally. All reporting metrics surrounding its FOC emissions follow the U.S. EPA's interim guidance for PFAS destruction and disposal, issued in April 2024.

CHEManager
Oct 15th, 2026
Albert raises $55M to scale chemistry-native AI.

Albert raises $55M to scale chemistry-native AI. Albert, developer of the first chemistry-native AI operating system for R&D, announced a $55 million Series B funding. The Series B funding is led by TCV with participation from new investors Delta-V Capital, Socium Ventures, HighSage Ventures, Coral Capital, and Legion VC. They are joined by existing investors Coatue, J.P. Morgan Growth Equity Partners, Index Ventures, and Applied Ventures. The new funding will be used to expand Albert's chemistry-native AI capabilities, shortening development cycles and reducing time to market for the everyday products used by billions of people. As companies race to adapt to shifting safety and regulatory requirements, supply chain disruptions, and customer expectations for faster timelines, leveraging AI for product development is becoming increasingly critical. Albert was built specifically for the complexity of chemistry and materials science, combining chemistry-native AI with the security, governance, and scale required by global enterprises, including zero data retention, fine grained access controls, and reasoning audit trails. General-purpose models consistently fail to support specialized workflows in highly sensitive industries like legal, finance, and science. In enterprise R&D, scientists need highly specific AI capable of distinguishing between formulations, materials, processes, and experimental conditions that can look nearly identical in language but behave very differently in practice. Albert created a benchmark for formulation chemistry called "FormBench," which sets a new global standard for evaluating AI in this context. Albert also announced the industry-defining success of its chemistry-native model "Valence" which new research shows is 45x more accurate than general-purpose AI at retrieving the correct answers to scientific queries. Valence achieves this improved performance because it was trained to discriminate chemical composition and function while reading text, the way an experienced chemist would. "Enterprise AI for chemistry has to be built from the ontology up; the language, data, workflows, and decisions for R&D are deeply specialized. Because our team comes from the chemical industry, we've built Albert around that reality, pairing a scientific ontology with chemistry-native AI in a way that is tailored for each customer. This funding supports our vision of enabling customers to build a world model of their unique science, one that is grounded in their real experimental data," said Nick Talken, CEO and co-founder of Albert. "R&D in chemistry still runs largely on spreadsheets and institutional memory," said Morgan Gerlak, Partner, TCV. "Albert turns decades of lab data into faster discovery, and it represents what we think the future of vertical AI should look like." Albert's chemistry-native AI brings together the scientific ontology, intelligence, integrations, and regulatory compliance required to support R&D across large organizations, with partners such as AkzoNobel, Avient, BASF, Chemours, Clorox, Henkel, Kenvue, and Nouryon. Scientists can interact with natural language, and Ask Albert orchestrates a sophisticated harness of the tools, agents, and models to accelerate invention: surfacing institutional knowledge so teams don't repeat work, suggesting formulation candidates and designing experiments to shorten development cycles, and running complex data analysis to accelerate decisions. "We are proud of what we've accomplished together with Albert and are even more excited about the next steps on our shared roadmap. As a result of the partnership, we have increased R&D's ability to be interconnected across a common data platform, enabling the acceleration of how we develop new products for our consumers," said David Lutness, Head of R&D Digital Capabilities at Kenvue, maker of consumer health products like Zyrtec, Neutrogena, and Listerine. "In a global organization like ours, the challenge is never a lack of data, it's connecting it. Ask Albert lets our teams query everything in one place, from raw materials to notebook entries, instead of hunting across systems. We're still early, but it's clear this is going to reshape how we manage knowledge across R&D," said Milena Rosso-Vasic, Program Manager at one of the world's largest paint manufacturers, AkzoNobel. Over the past year, Albert has continued to expand across enterprise chemistry and materials R&D: Project creation has grown 26x year over year as organizations deploy Albert OS as shared infrastructure across their R&D functions. The user base has also multiplied, with 6x more scientists on Albert OS year over year, spanning 44 countries. This growth in adoption also includes increasingly diverse chemistry, with 4x more workflow creation year over year as more teams bring different R&D processes onto the platform. Albert's product capabilities have expanded just as rapidly: in six months, Ask Albert evolved from an AI search assistant to a full R&D partner that reasons across all of Albert OS. Company. 492 9th St, Suite 260 CA 94607 Oakland US

GlobeNewswire
Oct 14th, 2026
$CC investors: A Securities Fraud Class Action is pending on behalf of Chemours investors that lost money after 18% Stock Drop - Contact BFA Law by December 7 Deadline.

$CC investors: A Securities Fraud Class Action is pending on behalf of Chemours investors that lost money after 18% Stock Drop - Contact BFA Law by December 7 Deadline. Chemours has been sued for securities fraud after its stock plummeted 18.63% because Chemours allegedly misrepresented the strength of demand for its Opteon products. NEW YORK, Oct. 14, 2026 (GLOBE NEWSWIRE) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against The Chemours Company (NYSE:CC) and certain of the company's senior executives for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws. If you invested in Chemours, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/chemours-class-action-lawsuit. Key Details of the Chemours ($CC) Class Action: * Lead Plaintiff Deadline: December 7, 2026 * Alleged Misconduct: Securities fraud alleging Chemours misrepresented the strength of demand for its Opteon products * Stock Drop: August 5, 2026 - 18.63% Stock Drop * Court: U.S. District Court for the District of Delaware * Action: Contact BFA Law to discuss your rights Investors have until December 7, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Chemours securities. The class action is pending in the U.S. District Court for the District of Delaware. It is captioned Darcy v. The Chemours Company, No. 26-cv-1299. Why is Chemours Being Sued for Securities Fraud? Chemours offers a range of industrial and specialty chemical products, including Opteon, a set of refrigeration chemicals with a reduced ozone-depletion footprint. In late 2020, Congress enacted the U.S. AIM Act, which directed the EPA to oversee the transition to alternative refrigerants that present a lesser impact to the ozone layer. According to the complaint, Chemours stated that continued adoption of the AIM Act drove sustained growth for its Opteon products. Chemours stated that the "sustained double-digit" Opteon expansion would be "driven by the continued regulatory adoption" of the AIM Act. What's more, Chemours provided 2026 net sales guidance of 3% to 5% growth and 2026 adjusted EBITDA guidance of $800M - $900M, driven by "higher... demand" in its Opteon segment. As alleged, Chemours failed to disclose that customers were already oversupplied with Opteon products because of the AIM Act transition, leading to an "oversupplied channel heading into 2026." Why did Chemours's Stock Drop? On August 4, 2026, Chemours announced Q2 2026 financial results, revealing an approximately 1% year-over-year decrease in net sales and cutting 2026 adjusted EBITDA guidance by about 11% (to $775M - $825M from $800M - $900M). Chemours also revealed that customers had "built additional inventory" of Opteon products the prior year, that aftermarket channels had been filled, and that Chemours was selling into an "oversupplied channel heading into 2026." On this news, Chemours's stock dropped $3.34 per share, or 18.63%, from a closing price of $17.93 per share on August 4, 2026, to $14.59 per share on August 5, 2026. What Can You Do? If you invested in Chemours, you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360, and "SuperLawyers" by Thomson Reuters. Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients." BFA's notable successes include a recovery of over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. Attorney advertising. Past results do not guarantee future outcomes.

Business Wire
Oct 12th, 2026
The Chemours Company securities fraud Class Action result of overstatement of refrigerant aftermarket demand and 18% stock decline - investors may contact Lewis Kahn, esq., at Kahn Swick & Foti, LLC.

The Chemours Company securities fraud Class Action result of overstatement of refrigerant aftermarket demand and 18% stock decline - investors may contact Lewis Kahn, esq., at Kahn Swick & Foti, LLC. NEW YORK & NEW ORLEANS-(BUSINESS WIRE)-Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company ("Chemours" or the "Company") (NYSE: CC), if they purchased or otherwise acquired the Company's securities between February 20, 2026 and August 4, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Delaware. What You May Do If you purchased securities of Chemours as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3615 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-cc/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by December 7, 2026. About the Lawsuit Chemours and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On August 4, 2026, post-market, the Company announced its 2Q 2026 financial results and cut its full-year adjusted EBITDA guidance to $775-$825 million, down from $800-$900 million. On the earnings call the next morning, CEO Denise Dignam admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." CFO Shane Hostetter added that, "from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that... probably should have been allocated to more of this year." On this news, the price of Chemours' shares fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026. The case is Darcy v. The Chemours Company, et al., No. 26-cv-01299. KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services >>>For More Information about the case, Click HERE Contacts. Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-833-538-3615 1100 Poydras St., Suite 960 New Orleans, LA 70163

Associated Press
Oct 9th, 2026
Chemours faces securities fraud lawsuit over $65M in overstated aftermarket sales

The Law Offices of Frank R. Cruz has filed a securities fraud class action lawsuit against The Chemours Company on behalf of shareholders who purchased stock between 20 February and 4 August 2026. Shareholders have until 7 December 2026 to file a lead plaintiff motion. The lawsuit alleges that Chemours made materially false statements about its business operations. On 4 August 2026, the company reduced its full-year adjusted EBITDA guidance to $775 million to $825 million from the previous $800 million to $900 million. Management disclosed that aftermarket customers had built excess inventory, with approximately $65 million in aftermarket sales that should have been allocated to the current year. Following this announcement, Chemours shares fell 18.63% to close at $14.59 on 5 August 2026.